Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1993-10-28
pubmed:abstractText
In this institution, two antifibrinolytic agents have been in routine use before cardiopulmonary bypass (CPB) to prevent bleeding due to fibrinolysis; epsilon-aminocaproic acid (EACA) or tranexamic acid (TA) are administered as intravenous infusions over 2 hours, from the time of anesthetic induction until the onset of CPB. TA is 10 times more potent and binds more strongly to plasminogen than EACA. Data were collected retrospectively on 411 patients undergoing first-time coronary artery bypass grafting with cardiopulmonary bypass who had received one of four therapy regimens: 10 g of EACA (65 patients), 15 g of EACA (60 patients), 6 g of TA (100 patients), or 10 g of TA (75 patients). Patients who did not receive any drug (91) served as controls. Anesthetic technique and the heparin/protamine protocol did not differ. Blood collected by mediastinal and pleural tubes was autotransfused up to 6 hours postoperatively. Both TA and EACA reduced post-CPB bleeding in the first 24 hours. Ten grams of TA was the most effective, resulting in a 52% and 36% reduction in blood loss over controls at 6 and 24 hours, respectively. Although 10 g of TA was more effective than 6 g of TA in blood loss control for the first 6 hours, the difference was not significant at 24 hours. A significantly lower number of patients in the 10 g TA group received blood products than in control (28% v 49%) patients (P = 0.02). Pretreatment with 10 g of TA prevented excessive (over 750 mL in 6 hours) bleeding after CPB.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1053-0770
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
431-5
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:8104526-6-Aminocaproic Acid, pubmed-meshheading:8104526-Blood Loss, Surgical, pubmed-meshheading:8104526-Blood Transfusion, pubmed-meshheading:8104526-Cardiopulmonary Bypass, pubmed-meshheading:8104526-Coronary Artery Bypass, pubmed-meshheading:8104526-Erythrocyte Transfusion, pubmed-meshheading:8104526-Fibrinolysis, pubmed-meshheading:8104526-Hemoglobins, pubmed-meshheading:8104526-Heparin, pubmed-meshheading:8104526-Humans, pubmed-meshheading:8104526-Injections, Intravenous, pubmed-meshheading:8104526-Intraoperative Care, pubmed-meshheading:8104526-Middle Aged, pubmed-meshheading:8104526-Myocardial Revascularization, pubmed-meshheading:8104526-Postoperative Care, pubmed-meshheading:8104526-Premedication, pubmed-meshheading:8104526-Retrospective Studies, pubmed-meshheading:8104526-Time Factors, pubmed-meshheading:8104526-Tranexamic Acid
pubmed:year
1993
pubmed:articleTitle
Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid.
pubmed:affiliation
Department of Anaesthesia, Toronto Hospital, University of Toronto, Ontario, Canada.
pubmed:publicationType
Journal Article